Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer

Hua Hsi Wu, Peng Hui Wang, Jiun Yih Yeh, Yi Jen Chen, Ming Shyen Yen, Rui Lan Huang, Yueh Ju Tsai, Chiou Chung Yuan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p=0.001) and overall survival (29 months vs. 41 months, p=0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0ng/mL.

Original languageEnglish
Pages (from-to)30-34
Number of pages5
JournalTaiwanese Journal of Obstetrics and Gynecology
Volume53
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Keratin-19
Serum
Lymph Nodes
Platinum
Disease-Free Survival
Survival
Neoplasm Metastasis
Neoplasms
Differentiation Antigens
Retrospective Studies
Biomarkers
Ovarian epithelial cancer
Antigens
Mortality

Keywords

  • Cyfra 21-1
  • Cytokeratin 19 fragment
  • Epithelial ovarian cancer
  • Prognosis

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Medicine(all)

Cite this

Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. / Wu, Hua Hsi; Wang, Peng Hui; Yeh, Jiun Yih; Chen, Yi Jen; Yen, Ming Shyen; Huang, Rui Lan; Tsai, Yueh Ju; Yuan, Chiou Chung.

In: Taiwanese Journal of Obstetrics and Gynecology, Vol. 53, No. 1, 2014, p. 30-34.

Research output: Contribution to journalArticle

Wu, Hua Hsi ; Wang, Peng Hui ; Yeh, Jiun Yih ; Chen, Yi Jen ; Yen, Ming Shyen ; Huang, Rui Lan ; Tsai, Yueh Ju ; Yuan, Chiou Chung. / Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. In: Taiwanese Journal of Obstetrics and Gynecology. 2014 ; Vol. 53, No. 1. pp. 30-34.
@article{7f4bac51f8784f8f8cfc21f6e0d1af86,
title = "Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer",
abstract = "Objectives: Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p=0.001) and overall survival (29 months vs. 41 months, p=0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0ng/mL.",
keywords = "Cyfra 21-1, Cytokeratin 19 fragment, Epithelial ovarian cancer, Prognosis",
author = "Wu, {Hua Hsi} and Wang, {Peng Hui} and Yeh, {Jiun Yih} and Chen, {Yi Jen} and Yen, {Ming Shyen} and Huang, {Rui Lan} and Tsai, {Yueh Ju} and Yuan, {Chiou Chung}",
year = "2014",
doi = "10.1016/j.tjog.2013.02.002",
language = "English",
volume = "53",
pages = "30--34",
journal = "Taiwanese Journal of Obstetrics and Gynecology",
issn = "1028-4559",
publisher = "臺灣婦產科醫學會",
number = "1",

}

TY - JOUR

T1 - Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer

AU - Wu, Hua Hsi

AU - Wang, Peng Hui

AU - Yeh, Jiun Yih

AU - Chen, Yi Jen

AU - Yen, Ming Shyen

AU - Huang, Rui Lan

AU - Tsai, Yueh Ju

AU - Yuan, Chiou Chung

PY - 2014

Y1 - 2014

N2 - Objectives: Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p=0.001) and overall survival (29 months vs. 41 months, p=0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0ng/mL.

AB - Objectives: Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p=0.001) and overall survival (29 months vs. 41 months, p=0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0ng/mL.

KW - Cyfra 21-1

KW - Cytokeratin 19 fragment

KW - Epithelial ovarian cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84899126080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899126080&partnerID=8YFLogxK

U2 - 10.1016/j.tjog.2013.02.002

DO - 10.1016/j.tjog.2013.02.002

M3 - Article

VL - 53

SP - 30

EP - 34

JO - Taiwanese Journal of Obstetrics and Gynecology

JF - Taiwanese Journal of Obstetrics and Gynecology

SN - 1028-4559

IS - 1

ER -